Kumari et al. applied the PPARγ agonist pioglitazone to female Swiss albino mice with endometrial cancer and noted a significant increase in weekly body weight, improvement in mean survival time, and partial normalization of uterine tissue weight, in comparison with the standard chemotherapeutic agent, paclitaxel [46]. This evidence concerns the gene PPARG and endometrial cancer.